Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Broadcom
AVGO
|
$2.09B |
| 2 |
Mastercard
MA
|
$2.06B |
| 3 |
UnitedHealth
UNH
|
$1.3B |
| 4 |
Coca-Cola
KO
|
$1.17B |
| 5 |
Marsh & McLennan
MMC
|
$1.1B |
Top Sells
| 1 |
Alphabet (Google) Class A
GOOGL
|
$1.55B |
| 2 |
Apple
AAPL
|
$1.51B |
| 3 |
JPMorgan Chase
JPM
|
$1.34B |
| 4 |
General Dynamics
GD
|
$1.25B |
| 5 |
Wells Fargo
WFC
|
$1.17B |
Sector Composition
| 1 | Technology | 21.49% |
| 2 | Healthcare | 18.42% |
| 3 | Financials | 15.97% |
| 4 | Consumer Discretionary | 9.49% |
| 5 | Industrials | 8.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Absci
ABSI
$368M
| $811K | ﹤0.01% |
323,119
-29,686
| -8% | -$74.5K |
|
1652
Trevi Therapeutics
TRVI
$854M
| $802K | ﹤0.01% |
+127,452
| New | +$802K |
|
1653
4D Molecular Therapeutics
FDMT
$340M
| $799K | ﹤0.01% |
247,471
+70,192
| +40% | +$227K |
|
1654
Ligand Pharmaceuticals
LGND
$3.25B
| $795K | ﹤0.01% |
7,562
-41
| -0.5% | -$4.31K |
|
1655
iShares Russell 1000 Value ETF
IWD
$63.5B
| $790K | ﹤0.01% |
4,200
-54
| -1% | -$10.2K |
|
1656
Brookfield Renewable
BEPC
$5.96B
| $785K | ﹤0.01% |
+28,135
| New | +$785K |
|
|
LENZ
1657
LENZ Therapeutics
LENZ
$1.2B
| $784K | ﹤0.01% |
30,488
+2,272
| +8% | +$58.4K |
|
1658
Summit Therapeutics
SMMT
$19.3B
| $781K | ﹤0.01% |
40,492
+373
| +0.9% | +$7.2K |
|
1659
Ternium
TX
$6.79B
| $775K | ﹤0.01% |
24,859
-183,968
| -88% | -$5.73M |
|
1660
Rogers Communications
RCI
$19.4B
| $740K | ﹤0.01% |
27,709
-15,715
| -36% | -$420K |
|
1661
Liberty Global Class A
LBTYA
$4.05B
| $737K | ﹤0.01% |
+64,001
| New | +$737K |
|
1662
Dynavax Technologies
DVAX
$1.18B
| $736K | ﹤0.01% |
56,716
-3,061
| -5% | -$39.7K |
|
1663
SPDR S&P International Small Cap ETF
GWX
$773M
| $731K | ﹤0.01% |
22,857
-8,611
| -27% | -$275K |
|
1664
Pure Storage
PSTG
$25.9B
| $730K | ﹤0.01% |
16,480
-134,329
| -89% | -$5.95M |
|
|
TSVT
1665
DELISTED
2seventy bio
TSVT
| $729K | ﹤0.01% |
147,663
-108,906
| -42% | -$538K |
|
1666
Arcutis Biotherapeutics
ARQT
$2.06B
| $729K | ﹤0.01% |
46,640
-2,627
| -5% | -$41.1K |
|
1667
Abeona Therapeutics
ABEO
$353M
| $729K | ﹤0.01% |
153,121
+59,832
| +64% | +$285K |
|
1668
Supernus Pharmaceuticals
SUPN
$2.58B
| $728K | ﹤0.01% |
22,224
-1,276
| -5% | -$41.8K |
|
1669
Agios Pharmaceuticals
AGIO
$2.09B
| $717K | ﹤0.01% |
24,462
-1,027
| -4% | -$30.1K |
|
1670
Hormel Foods
HRL
$14.1B
| $705K | ﹤0.01% |
22,781
+1,765
| +8% | +$54.6K |
|
1671
Emergent Biosolutions
EBS
$404M
| $695K | ﹤0.01% |
142,966
+7,624
| +6% | +$37.1K |
|
1672
Annexon
ANNX
$238M
| $688K | ﹤0.01% |
356,480
+88,314
| +33% | +$170K |
|
1673
BioCryst Pharmaceuticals
BCRX
$1.74B
| $685K | ﹤0.01% |
91,348
+2,291
| +3% | +$17.2K |
|
1674
Robinhood
HOOD
$90B
| $677K | ﹤0.01% |
16,261
+486
| +3% | +$20.2K |
|
1675
Aldeyra Therapeutics
ALDX
$334M
| $675K | ﹤0.01% |
+117,475
| New | +$675K |
|